October 4, 2023
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
September 19, 2023
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
August 17, 2023
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
August 8, 2023
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
August 3, 2023
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
August 1, 2023
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
June 8, 2023
Revolution Medicines to Participate in Upcoming Investor Conferences
May 24, 2023
Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
May 8, 2023
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
May 1, 2023
Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023